What it is
TB-500 is a synthetic peptide fragment derived from thymosin beta-4, a naturally occurring protein involved in cell migration, vascular development, and tissue repair. It is used in regenerative medicine protocols for soft-tissue recovery, musculoskeletal concerns, and inflammation modulation — often paired with BPC-157.
TB-500 is not an FDA-approved pharmaceutical. It is compounded for off-label use under physician supervision. Most published research is preclinical or limited human data; the regenerative rationale is real but the regulatory framework is not the same as for an approved drug. Patients considering TB-500 should understand that distinction before beginning a protocol.
How Dr. Brown approaches it
Peptide therapy at Esvie begins with a clinical consultation, not a phone order. Dr. Brown reviews your history, the specific indication you are seeking treatment for, and any contraindications before TB-500 is prescribed.
If TB-500 is appropriate, a written protocol — dose, frequency, route, duration, and monitoring plan — is provided. The peptide itself is sourced from a licensed compounding pharmacy. Most protocols run four to six weeks of subcutaneous administration, with a structured break period between cycles. TB-500 is frequently sequenced or co-administered with BPC-157 when both are clinically indicated.
Patients are monitored throughout. Adverse events, lack of expected response, or evolving clinical picture are addressed in person, not by message.
What to expect
Consultation: An in-person visit with Dr. Brown. Reviews of medical history, current medications, the indication for peptide therapy, and what TB-500 can and cannot do.
Treatment cycle: Subcutaneous injection on a schedule typical for TB-500 protocols — often a loading phase followed by a maintenance phase across four to six weeks. Most patients self-administer at home after instruction.
Monitoring: A check-in midway through the cycle and at completion. Adjustments are made based on response. Multiple cycles may be appropriate for ongoing recovery work.
No downtime, no aftercare: Injection sites may be mildly tender briefly; nothing more.
Candidacy
Good candidates have a clear indication — recovery from soft-tissue injury, slow-healing musculoskeletal concerns, or vascular and inflammatory issues under physician supervision — and understand the off-label nature of peptide therapy.
Not a candidate if you are pregnant or nursing. Not a candidate with active untreated malignancy. Not a candidate looking to bypass first-line evidence-based treatment of a specific medical condition.
If TB-500 is not appropriate for your situation, Dr. Brown will say so. The peptide menu at Esvie is selective — not every patient who asks is a candidate, and that is the point.